SCHEMBL25654892

SCHEMBL25654892

c1ccc(-c2ccc(-c3cccc(-c4ccc(-c5ccccc5)cc4-c4cc5oc6ccccc6c5c5c4[nH]c4ccccc45)c3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 3/20 0.40
▸ PLA2G4A P47712 3/20 0.40
▸ HTT P42858 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CDK5 Q00535 3/20 0.39
▸ CDK5R1 Q15078 2/20 0.39
▸ DYRK1A Q13627 2/20 0.39
▸ GSK3A P49840 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ MAP3K11 Q16584 2/20 0.38
▸ MAP3K9 P80192 1/20 0.38
▸ PLA2G10 O15496 1/20 0.38
▸ CHEK1 O14757 3/20 0.36
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25996402 0.84 HPGD (0.47) HTTSMN1; SMN2HPGDMAPK1CDK5
SCHEMBL24408621 0.83 CDK4 (0.43) PLA2G2APLA2G4AHTTSMN1; SMN2PLA2G10
SCHEMBL22180563 0.74 PLA2G2A (0.41) PLA2G2APLA2G4ASMN1; SMN2HPGDCDK5
SCHEMBL17451755 0.74 GABRP (0.44) PLA2G2APLA2G4ACDK5CDK5R1DYRK1A
SCHEMBL23183481 0.74 CDK5 (0.35) PLA2G2APLA2G4AHTTSMN1; SMN2HPGD
SCHEMBL17885202 0.74 CASP3 (0.43) PLA2G2APLA2G4AHTTSMN1; SMN2HPGD
SCHEMBL28380903 0.73 PARP14 (0.47) HTTSMN1; SMN2HPGDMAPK1MEN1
SCHEMBL31139211 0.73 PARP14 (0.47) HTTSMN1; SMN2HPGDMAPK1MEN1
SCHEMBL24882815 0.72 CDK4 (0.48) HTTSMN1; SMN2HPGDMAPK1CDK5
SCHEMBL25703026 0.72 PLA2G2A (0.46) PLA2G2APLA2G4ACDK5CDK5R1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165130-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165130-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CYP1A1, CYP2E1, AOX1 PLA2G2A 4388/4885PLA2G4A 4415/4885HTT 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback